Dyne Therapeutics, Inc.
DYN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,218 | $794 | $602 | $605 |
| - Cash | $435 | $122 | $172 | $201 |
| + Debt | $24 | $27 | $30 | $33 |
| Enterprise Value | $1,807 | $700 | $461 | $437 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$2 | -$2 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$315 | -$233 | -$169 | -$149 |
| % Margin | – | – | – | – |
| Net Income | -$317 | -$236 | -$168 | -$149 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.37 | -3.95 | -3.23 | -2.93 |
| % Growth | 14.7% | -22.3% | -10.2% | – |
| Operating Cash Flow | -$292 | -$188 | -$154 | -$120 |
| Capital Expenditures | -$2 | -$1 | -$3 | -$4 |
| Free Cash Flow | -$295 | -$189 | -$157 | -$123 |